Physician profile
Bhavani Moparty
NPI 1811023542
$3,868.96
in general payments reported to CMS, 2019-2025
32 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $185 · 2022: $441 · 2023: $782 · 2024: $1,129 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Education: $45.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.68 |
| Education | $45.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,247.58 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $363.35 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.32 | 2019-2025 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $224.47 | 2019-2025 | Suflave, Sutab |
| Boston Scientific Corporation | $194.09 | 2024 | |
| Allergan, INC. | $169.81 | 2019-2020 | |
| Janssen Biotech, INC. | $139.69 | 2019-2024 | Stelara |
| Heartflow, INC. | $131.18 | 2025 | |
| Celgene Corporation | $113.22 | 2023-2024 | Zeposia |
| Lucid Diagnostics INC. | $111.44 | 2025 | |
| Pfizer INC. | $100.06 | 2022-2024 | |
| Lilly USA, LLC | $96.81 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $85.60 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $67.56 | 2023 | |
| Ironwood Pharmaceuticals, INC | $65.24 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $64.21 | 2022-2023 | Gimoti |
| Genzyme Corporation | $62.23 | 2024 | |
| Ardelyx, INC. | $51.96 | 2024 | Ibsrela |
| Celltrion USA INC. | $41.51 | 2023-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $40.39 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $34.60 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $26.82 | 2019-2022 | |
| Novo Nordisk INC | $25.50 | 2025 | Wegovy |
| Enterra Medical, INC. | $22.81 | 2024 | |
| Ferring Pharmaceuticals INC. | $21.93 | 2023 | Clenpiq |
| Adc Therapeutics America, INC. | $20.05 | 2025 | |
| Aimmune Therapeutics, INC. | $16.86 | 2024 | |
| Qol Medical, LLC | $16.18 | 2023 | Sucraid |
| Cumberland Pharmaceuticals, INC. | $15.53 | 2019 | |
| Shionogi INC | $13.05 | 2019 | |
| Olympus America INC. | $11.91 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavani Moparty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.